CIS Pharma is a privately held biopharmaceutical company. We develop next-gen immuno-conjugates, ADCs and radioligand therapies for cancer patients with poor prognosis and prone to high spread of metastases.
Our assets include targeting moieties against CD 171 and CD 276, and a linker/carrier technology to overcome the current limitations of immuno-conjugates to create highly unfiform and very stable conjugates with DAR up to 16, as well as with combination of different drugs for targeted combination therapies on the same carrier.
-------------
L1CAM
is an internalizing target with a high rate of receptor recycling. Over-expression promotes metastatic spread and resistance to chemotherapy. L1CAM is also a cancer stem cell-specific target, involved in stem-cell processes. CIS Pharma’s anti-L1CAM mAb is based on a chimeric mAb that was in human. We have humanized and optimized an anti-L1CAM antibody, created an Fc-silenced, a-glycosylated binder, and have identified our clinical lead, pat.pend. Biodistribution is extremely favorable, offering an attractive therapeutic window. We have also demonstrated our radioligand to be highly effective against ovarian cancer in a mouse xenograft model. Based on these findings we plan to start IND enabling studies in Q3.2023 and enter clinical phase I in 2025.
-------------
B7H3
comprises a very attractive pan-cancer potential and is highly overexpressed in all relevant types of solid tumors. B7H3 is an internalizing target, its expression promotes metastatic spread and resistance to chemotherapy. It suppresses T-cell activation, thereby inhibiting tumor-antigens-specific immune response. We have developed two nanobody candidates, currently being produced, a biodistribution study is planned for Q2.2023. There is interest in our nanobody assets expressed by biotechs active in radioligand therapy. We plan to progress this format into clinical stage as it is a suitable for a theranostic radioligand approach.
---------------
LINKER
CIS Pharma is a linker chemistry powerhouse with a technology platform highly attractive to develop the next generation ADCs. Based on our site-specific linker technology we create highly uniform conjugates comprising linker more stable than those currently marketed. Our linker technology also comprises a polymer carrier customizable in number of binding sites, in length and in hydrophilicity. Both the monomers and polymers are non-toxic. Our polymer carrier is non-biodegradable, and the conjugation chemistry of the carrier is bioorthogenal. Based on the technology we create ADCs with DAR up to 16, with the same or with two different, synergetic payloads, such as radiosensitizer and radionuclides. The linker/carrier technology also enables us to conjugate a higher number of payloads to smaller targeting formats such as nanobodies that comprise one active handle only. In a biodistribution study we demonstrate the linker/carrier technology not to impair targeting. Partners with targeting moieties and/or payloads will benefit from the linker technology as we enable the industry to produce unrivalled ADCs that are more stable, uniform and entail a higher DAR compared to current state-of-the-art.
Our assets include targeting moieties against CD 171 and CD 276, and a linker/carrier technology to overcome the current limitations of immuno-conjugates to create highly unfiform and very stable conjugates with DAR up to 16, as well as with combination of different drugs for targeted combination therapies on the same carrier.
-------------
L1CAM
is an internalizing target with a high rate of receptor recycling. Over-expression promotes metastatic spread and resistance to chemotherapy. L1CAM is also a cancer stem cell-specific target, involved in stem-cell processes. CIS Pharma’s anti-L1CAM mAb is based on a chimeric mAb that was in human. We have humanized and optimized an anti-L1CAM antibody, created an Fc-silenced, a-glycosylated binder, and have identified our clinical lead, pat.pend. Biodistribution is extremely favorable, offering an attractive therapeutic window. We have also demonstrated our radioligand to be highly effective against ovarian cancer in a mouse xenograft model. Based on these findings we plan to start IND enabling studies in Q3.2023 and enter clinical phase I in 2025.
-------------
B7H3
comprises a very attractive pan-cancer potential and is highly overexpressed in all relevant types of solid tumors. B7H3 is an internalizing target, its expression promotes metastatic spread and resistance to chemotherapy. It suppresses T-cell activation, thereby inhibiting tumor-antigens-specific immune response. We have developed two nanobody candidates, currently being produced, a biodistribution study is planned for Q2.2023. There is interest in our nanobody assets expressed by biotechs active in radioligand therapy. We plan to progress this format into clinical stage as it is a suitable for a theranostic radioligand approach.
---------------
LINKER
CIS Pharma is a linker chemistry powerhouse with a technology platform highly attractive to develop the next generation ADCs. Based on our site-specific linker technology we create highly uniform conjugates comprising linker more stable than those currently marketed. Our linker technology also comprises a polymer carrier customizable in number of binding sites, in length and in hydrophilicity. Both the monomers and polymers are non-toxic. Our polymer carrier is non-biodegradable, and the conjugation chemistry of the carrier is bioorthogenal. Based on the technology we create ADCs with DAR up to 16, with the same or with two different, synergetic payloads, such as radiosensitizer and radionuclides. The linker/carrier technology also enables us to conjugate a higher number of payloads to smaller targeting formats such as nanobodies that comprise one active handle only. In a biodistribution study we demonstrate the linker/carrier technology not to impair targeting. Partners with targeting moieties and/or payloads will benefit from the linker technology as we enable the industry to produce unrivalled ADCs that are more stable, uniform and entail a higher DAR compared to current state-of-the-art.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
